Interestingly, 2-Hydroxypropyl-B-Cyclodextrin, a solubilizing agent of lipophilic compounds that is currently used on a Phase 2b/3 clinical trial for Niemann Pick disease (an autosomal recessive lysosomal storage disorder), was found to mitigate the disease-associated phenotypes of PD hMOs with biallelic pathogenic PINK1 variants, but in this case, its action is apparently via enhancing autophagy and mitophagy capacity in PINK1-deficient neurons [209]. Here, PINK1 is linked to Niemann-Pick disease.